Drugs / ENT-01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03938922 | Mar 2024 → Jun 2025 | Parkinson disease, dementia | Enterin Inc. | Withdrawn | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT03047629 | May 2017 → Apr 2018 | Parkinson disease, constipation disorder | Enterin Inc. | Completed | Met primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04483479 | Jul 2020 → Feb 2022 | Parkinson disease, constipation disorder | Enterin Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03781791 | Dec 2018 → Dec 2021 | Parkinson disease, constipation disorder | Enterin Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03047629 ↗ |
| Known as | squalamine | “OBJECTIVE: We sought to evaluate the safety of ENT-01 oral tablets (a synthetic squalamine salt), its pharmacokinetics, and its effect on bowel function in PD patients with...” PMID 34316590 ↗ Jul 2019 |
| Action | Inhibit | “through this mechanism suppresses aggregation of αS monomers into neurotoxic oligomers” PMID 34316590 ↗ Jul 2019 |
| Route | Oral | “ENT-01 oral tablets” PMID 34316590 ↗ Jul 2019 |